Five Prime Therapeutics Terminates Research and Collaboration Agreement with INBRX 110 LP

Five Prime Therapeutics (FPRX) disclosed in a regulatory filing that it has delivered to INBRX 110 LP, or Inhibrx, a written notice of termination of the research collaboration and license agreement between the companies.

Under this agreement, FivePrime obtained from Inhibrx an exclusive, worldwide license to antibodies to glucocorticoid-induced tumor necrosis factor receptor for therapeutic and diagnostic uses, and an exclusive option to obtain exclusive, worldwide licenses to multi-specific antibodies developed by Inhibrx that bind to both GITR and other targets.

FivePrime delivered to Inhibrx written notice of termination of the agreement for convenience. Pursuant to the terms of the agreement, termination will become effective on Dec. 27, which is 120 days after the effective date of FivePrime’s notice of termination.

Leave a Comment